PHARM Pharming Group NV

Pharming Group to report third quarter 2024 financial results on October 24

Pharming Group to report third quarter 2024 financial results on October 24

Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.



Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on October 24, 2024.

To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.

Conference call registration:

Please note, the Company will only take questions from dial-in attendees.

To watch the live webcast, please register in advance using the link below.

Webcast registration:

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit and find us on .

For further public information, contact:

Pharming Group, Leiden, the Netherlands

Michael Levitan, VP Investor Relations & Corporate Communications

T: +1 (908) 705 1696

E:

FTI Consulting, London, UK

Victoria Foster Mitchell/Alex Shaw/Amy Byrne

T: 0

LifeSpring Life Sciences Communication, Amsterdam, the Netherlands

Leon Melens

T: 27

E:

Attachment



EN
10/10/2024

Underlying

PHARMPharming Group NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharming Group NV

 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming Group announces the filing of its 2025 Annual Report and Form...

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. The Annual Report is available at and under Investors/Financial documents on the Pharming.com website. The Company also announced the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The 2025 Annual Report on Form 20-F can be found under Investors/SEC...

April 2, 2026 1 EN
 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib)...

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on Phase II/III clinical data demonstrating statistically significant impact on measures of immune dysregulation and immunodeficiencyFinal European Commission decision expected in Q2 2026 Leiden, the Netherlands, March 27, 2026: Phar...

March 27, 2026 1 EN
 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming Group announces approval of Joenja® (leniolisib) in Japan for...

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients aged 12 years and older and a multinational pediatric study in children aged 4 to 11 yearsFirst approval of Joenja covering children aged 4 to 11 with APDS Leiden, the Netherlands, March 24, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: ...

March 24, 2026 1 EN
 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming Group reports fourth quarter and full year 2025 financial res...

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib) Fourth quarter 2025 total revenues increased by 15% to US$106.5 million, compared to the fourth quarter 2024RUCONEST® full year revenue increased by 26% to US$317.9 million and fourth quarter revenue increased by 9% to US$86.7 millionJoenja® revenue increased by 29% to US$58.2 million and fourt...

March 12, 2026 1 EN
 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming Group announces 2026 financial guidance and highlights rare d...

Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth)2026 total operating expense guidance of US$330 – US$335 millionInvestor Day will be webcast today starting at 10:00 am EST (16:...

February 3, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch